drugset / Trial / NCT00352950
Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panitumumab | Monoclonal antibody | — | — |
| Subject | Sirolimus | Small molecule | — | — |